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Summary Systemic lupus erythematosus (SLE) is
a heterogeneous disease with a vast variety of clini-
cal manifestations. Timely diagnosis is important for
gaining access to specific therapy and care. In this
survey, we asked SLE patients with an established
diagnosis to report about their personal history and
their daily life with SLE in order to gain knowledge
about diagnostics, treatment pathways and poten-
tial problems in daily living and functioning. In most
cases, the diagnosis of SLE was made by a specialist in
rheumatology or dermatology. Of the patients 41.5%
were diagnosed within the first year after onset of
disease symptoms, while 37.3% of the patients waited
for 3 or more years for the final diagnosis of SLE.
Interestingly, we found no differences with respect
to patients living in urban or rural areas. Specific
therapy worked well in many but not in all patients:
the majority of patients reported problems with paid
work, social life and leisure activities including trav-
eling. Patients reported a need for better information
for the general public about SLE. In addition, they
wanted be better informed themselves. Despite all
successful efforts in recent years, there is still room
for improvement with respect to early diagnosis, early
start of specific therapy and for better information of
the public on the mysterious disorder named SLE.
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Systemic lupus erythematosus (SLE) is a multiorgan
disorder and can present with different clinical fea-
tures due to a variable involvement of internal organs,
the musculoskeletal system, the nervous system, the
skin or the hematopoietic system. One of the main
difficulties in SLE is to make a correct and timely diag-
nosis since diagnosis criteria are still missing and the
existing classification criteria are not perfectly suit-
able for (early) diagnosis, despite some changes in
the recent past [1–3]. In addition, many common SLE
symptoms are relatively unspecific (such as fever and
anemia) and SLE patients often suffer from combina-
tions of various symptoms or organ manifestations.
The prevalence of SLE in European studies lies be-
tween 25 and 91 per 100,000 persons which would
account for an estimated approximation of 4000 SLE
patients in Austria with 90% of being female [4]. As
in other countries, Austrian SLE patients are treated
by different specialists because of historical reasons
and/or because of the leading set of symptoms. Re-
cently, a Swiss group reported a cross-sectional anal-
ysis of clinical characteristics and treatments across
different medical disciplines in Switzerland [5]. Due
to the heterogeneity of the disease and the possibil-
ity of life-threatening organ manifestations, SLE pa-
tients are preferably treated in larger (tertiary) centers
which offer a multidisciplinary approach, but espe-
cially milder forms are also treated in an extramu-
ral setting. Given the fact that early diagnosis is im-
portant but difficult, we asked our patients how long
they waited for a final diagnosis, which doctor ac-
tually made it, how many physicians/specialists they
had to visit before a final diagnosis was made and if
there were differences between patients living in ru-
ral or urban areas. Although SLE can affect essen-
tially all organ systems, up to 95% of SLE patients
suffer from inflammation, pain and malfunction of
the musculoskeletal system leading to activity limi-
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Fever 41.5% Swollen LN 16.1%
Rash 37.3% Angina pectoris 15.3%
UV intolerance 28.0% Thrombosis 13.6%
Depression 25.4% Dyspnea 12.7%
Raynaud’s
phenomenon
23.7% Oral/genital ulcers 10.2%
Edema 23.7%





General practitioner 6.8% 7/7%
Neurologist 3.4% 6/0%




Time to diagnosis All patients Domicile Education
Urban/rural University/
compulsory
<1 year 41.5% 42/40% 44/35%
1-3 years 21.2% 22/20% 26/25%
3-6 years 9.3% 5/16% 9/5%
6-12 years 16.1% 16/16% 15/25%
>12 years 11.9% 14/9% 6/10%
NSARD nonsteroidal antirheumatic drugs, LN lymph nodes, UV ultraviolet
tations and participation restrictions in daily life [6,
7]. In a previous qualitative study, we explored the
array of concepts important to patients with chronic
SLE and compared these to instruments assessing dis-
ease activity, damage and health status. A wide range
of concepts were identified; however, only a small
number were found to be covered by the instruments
commonly used in clinical practice and research [6].
Therefore, the patients’ perspective on rheumatic dis-
eases came into the focus of interest, but data in gen-
eral and such on Austrian patients, in particular, are
scarce. In this survey, we asked SLE patients with
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an established diagnosis to report about their per-
sonal history and their daily life with SLE in order
to gain knowledge about diagnostics, treatment path-




A survey was conducted with a self-developed ques-
tionnaire that we piloted and adapted after a prelimi-
nary test with 10 patients.
Patients
Patients were informed about this survey via flyers
and posters which were on display in outpatient wards
and doctors’ offices of dermatologists and rheumatol-
ogists. In addition, we created the homepage www.
lebenmitlupus.org (i. e. living with lupus) as a tool
of information for patients and their relatives. In or-
der to participate in our survey, questionnaires could
be submitted either online or per mail. In order to
ensure anonymity and to keep the questionnaire sim-
ple, we provided ticking options for most of the an-
swers, asking either for a yes/no decision or asked
to choose from four different grades of approval. We
chose this approach since anonymity was of high im-
portance for questions related to employment (e. g.
does your employer know about your disease?) or so-
cial situation and not easily achieved in this rare dis-
ease. Recruitment lasted from 1 January to 31 Decem-
ber 2013. The questionnaires were distributed and
processed by Public Health PR, Vienna (http://www.
publichealth.at/), and the project “Leben mit Lupus”
(i. e. living with lupus) was financially supported by
GlaxoSmithKline. This questionnaire survey was done
in agreement with local laws (Wiener Krankenanstal-
tengesetz §15 Abs. 3, as confirmed by the ethics com-
mittee of the City of Vienna, 16-261-VK, 2016).
Statistical analysis
The questionnaire consisted of 30 questions in 5 cate-
gories (i.e. route to diagnosis, therapy, social environ-
ment, information and communication and demo-
graphic data). Only fully completed questionnaires
were used for the analysis. We used the following
procedure to check that patients with SLE did not
fill in the questionnaire more than once: question-
naires with identical answers submitted within 1 h
were counted only once. Descriptive statistics were
used to describe the answers of the patients. For
categorical variables (e. g. sex/gender, medication),
the absolute frequency (n =) and the percentage fre-
quency (%) were calculated and reported.
Results
A total of 125 questionnaires were received and of
these, 118 were complete and could be included in
the analysis. The demographic data of the partici-
pants are reported in Table 1.
Most patients presented with fatigue, arthralgia,
rash and fever of unknown origin and thus with typ-
ical but relatively unspecific symptoms [8]. An early
diagnosis (within the first year) was made in 41.5%,
an additional 21.2% had SLE diagnosis within the first
3 years, but for more than one third of SLE patients,
diagnosis took more than 3, in some cases even more
than 12 years (Table 1). Unexpectedly, early diagnosis
was not higher in patients living in urban than in
those living in rural areas (42% vs. 40%, respectively),
but appeared slightly higher in patients with a higher
education: 70% of patients in the best educated group
had SLE diagnosis within 3 years compared to 60%
in the lowest educated group (Table 1, Fisher’s exact
test p = n. s.) and also the percentage of patients with
delayed diagnosis (>6 years) was slightly higher in less
educated patients (35% vs. 21% in the best educated
group).
In general, most patients were seen first by a gen-
eral practitioner (67%), but the final diagnosis was
made by a rheumatologist (50.9%) or dermatologist
(22.0%) (Fig. 1; Table 1). In 43% of patients 1–3 doc-
tors were involved, the rest needed more contacts for
SLE diagnosis. Again, there was no difference between
patients from urban or rural areas (Table 1).
Patients received standard of care therapy (SOC),
including non-steroidal antirheumatic drugs (NSARD),
steroids, antimalarial drugs and other immunomod-
ulators and, in a small number, also biologicals (Ta-
ble 1). Of the patients 66% reported an improvement
of their physical symptoms under therapy. Conse-
quently, the number of patients rating their overall
physical condition “very poor” was reduced from 55%
to 18% under therapy, yet only 17% reached a state
where they felt “good” (rating possibilities were good,
moderate, poor and very poor). In addition, 54%
of patients also reported an improvement in their
mental condition. In summary, SOC worked, but did
not lead to remission in all patients. As expected
from personal contact and from the literature [9, 10],
the majority of patients reported problems with paid
work, social life and leisure activities including trav-
eling (Fig. 2). Interestingly, most of the same patients
did not report difficulties in their partnership or fam-
ily. More than 80% lived in a partnership/marriage. It
is noteworthy that more than 69% reported problems
with respect to their job and social situation at their
working place, but only 57% informed their employer
about their disease and 67% informed at least their
closest colleagues. Comparing patients with the high-
est and the lowest level of education, both groups
reported very similar frequent problems (74% and
77%, respectively). Nevertheless, the vast majority
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Fig. 1 First visit andfinal SLEdiagnosis. 67%ofpatientshad
their first visit for SLEsymptomsat their general practitioner
(GP,a), but diagnosiswasmadeby the respective special-
ists,mainlyby rheumatologists, dermatologists andgeneral
internists (b)
of SLE patients explained the wish that the rest of
the population should be better informed about the
disease per se (82.2%).
Patients received information about SLE primar-
ily from their doctors (82.2%) and from web-based
sources (68.6%), also from brochures (23.7%), other
print media (14.4%), or from self-help groups (16.1%),
but rarely from books (5.9%) or at pharmacies (1.7%).
Discussion
This survey describes the current situation of SLE pa-
tients in Austria related to the course of disease and
the problems in daily life. The most unexpected find-
ings were the high proportion of patients having a la-
tency period of more than 3 years to being diagnosed
Fig. 2 Social life. Patientswere asked for disease-relateddis-
advantageswith respect to their job, social situation ingeneral,
special situationwithpartneror family, travelingand leisure time
activities. Valuesaregivenas thepercentageof positive reports
with SLE, that living in urban or rural areas did not
make a big difference with this respect, and that only
a small number of patients rated their condition as
“good” despite intensive therapy.
Our study has some limitations based on the na-
ture of the questionnaire, which we designed in the
attempt to keep it short, simple and anonymized. On
the other hand, patients trusted our efforts and ac-
cepted the questionnaire despite its limitations. The
sample size is to our knowledge the largest so far deal-
ing with the perspective of Austrian SLE patients on
their personal history with SLE.
Although patients presented with typical (although
relatively non-specific) symptoms, more than one
third of SLE patients waited 3 years or longer for a fi-
nal diagnosis and, thus, specific therapy. As in other
rheumatic diseases, early diagnosis and consequently
early therapy in SLE is necessary and should be im-
proved in order to avoid damage brought about by
the disease itself or by disease-related comorbidities
[11]. As in most cases, SLE diagnosis has been made
by a specialist (rheumatologist, followed by dermatol-
ogist and unspecified specialist in internal medicine),
an easy access to specialized persons is essential,
as it is with other inflammatory rheumatic diseases
[12, 13]. Recently, an Austrian group analyzed the
interface management between general practitioners
and rheumatologists in a survey and tried to define
a concept for future joint recommendations [14]. In-
terestingly and against our expectations, there were
no differences in time to diagnosis between patients
form urban and rural areas. An explanation might be
that general practitioners from rural areas (who are
the first to see SLE patients in most cases) refer their
patients to specialists in internal medicine, rheuma-
tology or dermatology (who make the final diagnosis)
The patients’ perspective: living with lupus in Austria K
original article
in a very similar manner as their colleagues do in
urban environments.
Although SLE therapy has gained a lot of options
in recent years, there is still a much too high number
of patients regarding their physical status as “poor”
or “very poor” despite therapy. In addition, patients
also still experience disadvantages in crucial aspects
of their daily life, including their job and general social
situation at their working place as well as during trav-
eling and leisure activities. These problems appear
to be aggravated in situations when patients have to
cooperate with persons who are not informed about
their disease or about SLE in general, since many pa-
tients do not inform their employers or closer social
environment. Consequently, these patients see a need
for better information of the general public about SLE
and they also want to be better informed themselves.
Many efforts have been made in the last years to
make SLE therapy more effective and more precise as
well as to understand the disease from the patients’
perspective and to design better tools for assessing
SLE. Despite all successful efforts in recent years, there
is still room for improvement with respect to early di-
agnosis, early start of specific therapy and for informa-
tion of the public on the mysterious disorder named
SLE.
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